Less than 24 hours after offering to purchase Genzyme for $18.5 billion, Sanofi-Aventis was sent a letter of rejection from the biotech firm’s board of directors stating that the offer just wasn’t worth it.
“Without exception, each member of the Genzyme board believes this is not the right time to sell the company, because your opportunistic [...]
Genzyme Snubs Sanofi Offer